# US 2021/0278398 A1 · Nucleic acid linked immune-sandwich assay (nulisa)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0278398 A1
- Document ID: US20210278398A1
- Status: Published application
- Kind: A1
- Application number: 17/330,331
- Filed: 2021-05-25
- Published: 2021-09-09
- Earliest claimed: 2019-12-03
- Assignees: Alamar Biosciences, Inc.
- Applicants: Alamar Biosciences, Inc.
- Inventors: Yuling Luo; Wei Feng; Adrian Grzybowski; Yiyuan Yin; Shiping Chen
- Web page: https://patentgrep.com/patent/US20210278398A1

## CPC

- G01N 33/54306: {Solid-phase reaction mechanisms}
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/244: {Interleukins [IL]}
- C07K 16/247: {IL-4}
- C07K 16/248: {IL-6}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6813: Hybridisation assays
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 2333/71: for growth factors; for growth regulators
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein are highly sensitive immunoassays that utilize a capture/release mechanism to reduce non-specific binding and achieve detection with attomolar-level sensitivity. Kits that can be used for carrying out these highly sensitive immunoassays are also disclosed herein.

## Claims

### Claim at position 1

1-284. (canceled)

### Claim 285

An assay method for detecting an analyte in a sample, comprising:
(1) mixing a first binding moiety and a second binding moiety and the sample in a solution, wherein:
(i) the first binding moiety comprises a first antibody or a first antibody fragment that specifically binds the analyte, a first nucleic acid tag that comprises a poly-A or poly-T sequence and is conjugated to the first antibody or the first antibody fragment, and a first nucleic acid target label that hybridizes with the first nucleic acid tag;
(ii) the second binding moiety comprises a second antibody or a second antibody fragment that specifically binds the analyte, a second nucleic acid tag that comprises a second nucleic acid target label and is conjugated to the second antibody or the second antibody fragment, and a nucleic acid probe that is conjugated with biotin and hybridizes with the second nucleic acid tag; and
(iii) the first antibody or the first antibody fragment and the second antibody or the second antibody fragment bind to the analyte and form an immunocomplex;
(2) introducing first paramagnetic beads coupled with a poly-T or poly-A sequence and capturing the immunocomplex on the first paramagnetic beads by hybridization between the poly-A sequence from the first binding moiety and the poly-T sequence from the first paramagnetic beads, or between the poly-T sequence from the first binding moiety and the poly-A sequence from the first paramagnetic beads;
(3) washing the first paramagnetic beads to remove unbound molecules;
(4) releasing the immunocomplex from the first paramagnetic beads to the solution by disrupting the hybridization between the poly-A sequence from the first binding moiety and the poly-T sequence from the first paramagnetic beads, or between the poly-T sequence from the first binding moiety and the poly-A sequence from the first paramagnetic beads;
(5) introducing second paramagnetic beads coupled with streptavidin and recapturing the immunocomplex on the second paramagnetic beads via binding between the biotin from the second binding moiety and the streptavidin from the second paramagnetic beads;
(6) washing the second paramagnetic beads to remove unbound molecules;
(7) introducing to a solution containing the second paramagnetic beads a single-stranded nucleic acid connector that comprises a first segment hybridizing with the first nucleic acid target label, and a neighboring second segment hybridizing with the second nucleic acid target label, and completing proximity-based ligation between the first and second nucleic acid target labels following hybridization between the single-stranded nucleic acid connector and the first and second nucleic acid target labels in the immunocomplex to generate a nucleic acid reporter that bridges the first and second nucleic acid target labels; and
(8) detecting the nucleic acid reporter, thereby detecting the analyte.

### Claim 286

An assay method for detecting an analyte in at least two samples, comprising:
(1) mixing a first binding moiety and a second binding moiety and the sample in a solution, wherein:
(i) the first binding moiety comprises a first antibody or a first antibody fragment that specifically binds the analyte, a first nucleic acid tag that comprises a poly-A or poly-T sequence and is conjugated to the first antibody or the first antibody fragment, and a first nucleic acid target label that comprises a first identity barcode (“ID”) that is analyte-specific (“target ID”) and hybridizes with the first nucleic acid tag;
(ii) the second binding moiety comprises a second antibody or a second antibody fragment that specifically binds the analyte, a second nucleic acid tag that comprises a second nucleic acid target label and is conjugated to the second antibody or the second antibody fragment, wherein the second nucleic acid target label comprises a second target ID that is analyte-specific, and a nucleic acid probe that is conjugated with biotin and hybridizes with the second nucleic acid tag; and
(iii) the first antibody or the first antibody fragment and the second antibody or the second antibody fragment bind to the analyte and form an immunocomplex;
(2) introducing first paramagnetic beads coupled with a poly-T or poly-A sequence and capturing the immunocomplex on the first paramagnetic beads by hybridization between the poly-A sequence from the first binding moiety and the poly-T sequence from the first paramagnetic beads, or between the poly-T sequence from the first binding moiety and the poly-A sequence from the first paramagnetic beads;
(3) washing the first paramagnetic beads to remove unbound molecules;
(4) releasing the immunocomplex from the first paramagnetic beads to the solution by disrupting the hybridization between the poly-A sequence from the first binding moiety and the poly-T sequence from the first paramagnetic beads, or between the poly-T sequence from the first binding moiety and the poly-A sequence from the first paramagnetic beads;
(5) introducing second paramagnetic beads coupled with streptavidin and recapturing the immunocomplex on the second paramagnetic beads via binding between the biotin from the second binding moiety and the streptavidin from the second paramagnetic beads;
(6) washing the second paramagnetic beads to remove unbound molecules;
(7) introducing a partially double-stranded nucleic acid connector that comprises (i) a longer strand with a 5′ overhang and a 3′ overhang, wherein one of the overhangs hybridizes with the first nucleic acid target label and the other overhang hybridizes with the second nucleic acid target label; and (ii) a shorter strand comprising an ID that is sample-specific (“sample ID”); and hybridizing the 5′ overhang and the 3′ overhang of the partially double-stranded nucleic acid connector to the first nucleic acid target label and the second nucleic acid target label, and completing proximity-based ligation between (i) the first nucleic acid target label and the sample label and (ii) the second nucleic acid target label and sample label, to generate a nucleic acid reporter that comprises the first target ID, the sample ID, and the second target ID,
(8) pooling the nucleic acid reporters of at least two samples together; and
(9) detecting the nucleic acid reporter comprising the first target ID, the sample ID, and the second target ID, thereby detecting the analyte.

### Claim 287

An assay method for detecting an analyte in a sample, comprising:
(1) mixing a first binding moiety comprising a first binder and a first presenting group, a second binding moiety comprising a second binder and a second presenting group, and the sample in a solution, wherein:
(i) the first and second binders bind to the analyte and form an immunocomplex,
(ii) the immunocomplex is captured on a first solid surface in contact with the solution via binding between the first presenting group and a first receiving group coupled to the first solid surface,
(iii) the first binding moiety further comprises a first target label and the second binding moiety further comprises a second target label, and
(iv) wherein the first binder is an antibody or an antibody fragment that specifically binds the analyte and the second binder is an antibody or an antibody fragment that specifically binds the analyte;
(2) washing the first solid surface to remove unbound molecules;
(3) releasing the immunocomplex from the first solid surface by disrupting the binding between the first presenting group and the first receiving group;
(4) introducing a second solid surface and recapturing the immunocomplex on the second solid surface via binding between the second presenting group and the second receiving group coupled to the second solid surface;
(5) washing the second solid surface to remove unbound molecules;
(6) binding a connector to both the first target label and the second target label;
(7) generating a nucleic acid reporter from the immunocomplex by proximity-based ligation between the first target label and the second target label; and
(8) detecting the nucleic acid reporter, thereby detecting the analyte.

### Claim 288 (depends on 287)

The assay method of claim 287, wherein the first and second binders bind to non-overlapping epitopes on the analyte.

### Claim 289 (depends on 287)

The assay method of claim 287, wherein step (1) comprises forming the immunocomplex in the solution before capturing the immunocomplex on the first solid surface.

### Claim 290 (depends on 287)

The assay method of claim 287, wherein the releasing is by decreasing salt concentration or by increasing temperature to 70° C.

### Claim 291 (depends on 287)

The assay method of claim 287, wherein the method further comprising:
(i) a step (7a) before step (8), step (7a) comprising releasing the immunocomplex from the second solid surface by disrupting the binding between the second presenting group and the second receiving group, wherein optionally the releasing is by increasing temperature to 70° C. or by decreasing salt concentration;
(ii) a step (3a) before step (4), step (3a) comprising removing first solid surface; or
(iii) both (i) and (ii).

### Claim 292 (depends on 287)

The assay method of claim 287, wherein:
(i) the first presenting group is a first nucleic acid tag (the “first tag”) and the first receiving group is a first nucleic acid capture probe (the “first probe”), wherein the first probe or a fragment thereof is complementary to the first tag or a fragment thereof;
(ii) the second presenting group binds the second receiving group via biotin to streptavidin; or
(iii) both (i) and (ii).

### Claim 293 (depends on 292)

The assay method of claim 292, wherein the first tag comprises a poly-A sequence and the first probe comprises a poly-T sequence, or the first tag comprises a poly-T sequence and the first probe comprises a poly-A sequence.

### Claim 294 (depends on 287)

The assay method of claim 287, wherein the connector is a single-stranded nucleic acid molecule.

### Claim 295 (depends on 287)

The assay method of claim 287, wherein:
(i) the first solid surface comprises paramagnetic beads;
(ii) the second solid surface comprises paramagnetic beads; or
(iii) both (i) and (ii).

### Claim 296 (depends on 287)

The assay method of claim 287, wherein the detecting in step (8) comprises simultaneously detecting at least two analytes by simultaneously detecting the unique target label in the nucleic acid reporter associated with each analyte.

### Claim 297 (depends on 287)

The assay method of claim 287, wherein in step (9), detecting the analyte comprises co-detection of the first and the second target labels.

### Claim 298 (depends on 287)

The assay method of claim 287, wherein step (1) further comprising mixing a reference analyte into the sample or providing a dedicated reference sample.

### Claim 299 (depends on 287)

The assay method of claim 287, wherein the nucleic acid reporter is detected by multiplexed quantitative polymerase chain reaction (qPCR) or multiplexed digital PCR.

### Claim 300 (depends on 287)

The assay method of claim 287, wherein detecting further comprises normalizing the reporters generated from the analytes of the sample against the reporter generated from the reference analyte.

### Claim 301

An assay method for detecting an analyte in at least two samples, comprising:
(1) mixing a first binding moiety comprising a first binder and a first presenting group, a second binding moiety comprising a second binder and a second presenting group, and the samples in a solution, wherein:
(i) the first and second binders bind to the analyte and form an immunocomplex,
(ii) the immunocomplex is captured on a first solid surface in contact with the solution via binding between the first presenting group and a first receiving group coupled to the first solid surface,
(iii) the first binding moiety further comprises a first target label comprising a first identity barcode (“ID”) that is analyte-specific (“target ID”) and the second binding moiety further comprises a second target label comprising a second target ID, and
(iv) wherein the first binder is an antibody or an antibody fragment that specifically binds the analyte and the second binder is an antibody or an antibody fragment that specifically binds the analyte;
(2) washing the first solid surface to remove unbound molecules;
(3) releasing the immunocomplex from the first solid surface by disrupting the binding between the first presenting group and the first receiving group;
(4) introducing a second solid surface and recapturing the immunocomplex on the second solid surface via binding between the second presenting group and the second receiving group coupled to the second solid surface;
(5) washing the second solid surface to remove unbound molecules;
(6) binding a sample label comprising an ID that is sample-specific (“sample ID”) (i) to the first target label, (ii) to the second target label, or (iii) to both the first target label and the second target label;
(7) generating a nucleic acid reporter from the immunocomplex by proximity-based ligation between (i) the first target label and the sample label and (ii) the second target label and sample label, wherein the nucleic acid reporter comprises the first target ID, the second target ID, and the sample ID;
(8) pooling the nucleic acid reporters from the at least two samples; and
(9) detecting the nucleic acid reporters, thereby detecting the analyte.

### Claim 302 (depends on 301)

The assay method of claim 301, wherein the first and second binders bind to non-overlapping epitopes on the analyte.

### Claim 303 (depends on 301)

The assay method of claim 301, wherein step (1) comprises forming the immunocomplex in the solution before capturing the immunocomplex on the first solid surface.

### Claim 304 (depends on 301)

The assay method of claim 301, wherein the method further comprising:
(i) a step of (8a) before step (9), step (8a) comprising releasing the immunocomplex from the second solid surface by disrupting the binding between the second presenting group and the second receiving group, wherein optionally any of the releasing is by increasing temperature to 70° C. or decreasing salt concentration;
(ii) a step (3a) before step (4), step (3a) comprising removing the first solid surface; or
(iii) both (i) and (ii).

### Claim 305 (depends on 301)

The assay method of claim 301, wherein:
(i) the first presenting group is a first nucleic acid tag (the “first tag”) and the first receiving group is a first nucleic acid capture probe (the “first probe”), wherein the first probe or a fragment thereof is complementary to the first tag or a fragment thereof;
(ii) the second presenting group binds the second receiving group via biotin to streptavidin; or
(iii) both (i) and (ii).

### Claim 306 (depends on 305)

The assay method of claim 305, wherein the first tag comprises a poly-A sequence and the first probe comprises a poly-T sequence, or the first tag comprises a poly-T sequence and the first probe comprises a poly-A sequence.

### Claim 307 (depends on 301)

The assay method of claim 301, wherein the sample label is:
(i) a double-stranded nucleic acid molecule comprising two 5′ overhangs;
(ii) a double-stranded nucleic acid molecule comprising two 3′ overhangs;
(iii) a double-stranded nucleic acid molecule comprising a 5′ overhang and a 3′ overhang;
(iv) a double-stranded nucleic acid molecule comprising a 5′ overhang and a blunt end; or
(v) a double-stranded nucleic acid molecule comprising a 3′ overhang and a blunt end.

### Claim 308 (depends on 301)

The assay method of claim 301, wherein the sample label:
(i) hybridizes with the first target label via an overhang of the sample label;
(ii) hybridizes with the second target label via an overhang of the sample label; or
(iii) both (i) and (ii).

### Claim 309 (depends on 301)

The assay method of claim 301, comprising simultaneously detecting the unique sample ID in the nucleic acid reporter associated with each sample.

### Claim 310 (depends on 301)

The assay method of claim 301, comprising simultaneously detecting at least two analytes by simultaneously detecting the unique target ID in the nucleic acid reporter associated with each analyte.

### Claim 311 (depends on 301)

The assay method of claim 301, wherein in step (9), detecting the analyte comprises co-detection of the first and the second target IDs.

### Claim 312 (depends on 301)

The assay method of claim 301, wherein in step (1) further comprising mixing a reference analyte, and wherein optionally detecting further comprises normalizing the reporters generated from the analytes of the samples against the reporter generated from the reference analyte.

### Claim 313 (depends on 301)

The assay method of claim 301, wherein the nucleic acid reporter is detected by next generation sequencing (NGS).

### Claim 314 (depends on 301)

The assay method of claim 301, wherein:
(i) the first solid surface comprises paramagnetic beads;
(ii) the second solid surface comprises paramagnetic beads; or
(iii) both (i) and (ii).
